

南嶺蕘花活性成分之鑑定及其誘導人類白血病U937細胞凋亡與分化之機制

蔡瑞騏、廖慧芬；謝淳仁

E-mail: 9318470@mail.dyu.edu.tw

摘要

南嶺蕘花 (*Wikstroemia indica* C. A. Mey) 屬於瑞香科植物。分佈於台灣全境低海拔山地之叢林蔽蔭下。於中國民俗療法中，常利用南嶺蕘花做為抑制腫毒、關節炎、結核病、梅毒、與百日咳之治療。本研究利用南嶺蕘花之莖部，探討其化學成分及生物活性。結果純化出一屬於dicoumarin類的化合物daphnoretin及具有抗白血病之成分AF (Active Fraction)。南嶺蕘花的活性成分AF 31.3 ng/mL之劑量下直接作用於人類骨髓性白血病U937細胞，可造成U937細胞約80%之生長抑制率，但daphnoretin並沒此一生物活性。利用流式細胞儀分析其細胞週期，結果發現能夠造成細胞週期停滯於G0/G1期。AF (31.3 ng/mL) 可促進U937細胞達70%以上分化為單核球/巨噬細胞，75%以上的細胞表現NBT之還原活性，70%以上的細胞具有吞噬酵母菌的能力，以及70%的細胞表現出單核球表面抗原CD11b。同時亦伴隨有少量的凋亡細胞產生，以流式細胞儀分析結果發現，約16%之Sub-G1表現，且呈現劑量及時間依賴的關係。經由mitogen-activated protein kinase (MAPK) 抑制劑的分析，PD98059會影響AF對U937細胞生長與分化的作用，因此推論AF對U937細胞內訊息傳遞之機轉主要是透過MEK/ERK2之路徑。綜合以上結果，南嶺蕘花的活性成分AF能有效地抑制白血病細胞株U937之增生，以及誘導細胞之分化，而此作用機制可能與MAPK之途徑有關，是具有潛力之天然抗白血病藥物。

關鍵詞：南嶺蕘花；白血病；細胞分化；細胞凋亡；Mitogen-activated protein kinase

目錄

封面內頁 簽名頁 授權書 iii 中文摘要 iv 英文摘要 vi 誌謝 vii 目錄 viii 圖目錄 xii 表目錄 xiv 附錄目錄 xvi 縮寫表 xvii 第一章 緒論 1 第二章 文獻回顧 2 2.1 南嶺蕘花 (*Wikstroemia indica* C. A. Mey) 2 2.1.1 植株特徵 2 2.1.2 產地 2 2.1.3 採收加工 3 2.1.4 植物學分類 3 2.1.5 效用 3 2.1.6 毒性 3 2.1.7 已知成份 4 2.2 白血病 4 2.2.1 白血病之定義及分類 4 2.2.2 白血病之治療 5 2.2.3 關於誘導分化之研究 5 2.2.4 關於細胞凋亡之研究 9 2.3 MAPK之簡介 12 2.3.1 MAPK之簡介 12 2.3.2 ERK (extracellular signal-regulated kinase) 13 2.3.3 JNK (c-Jun NH₂-terminal kinase) 13 2.3.4 p38-MAPK 14 2.3.5 MAPK抑制劑 14 2.4 研究動機 15 第三章 材料與方法 16 3.1 儀器 16 3.2 化學藥劑及緩衝液 19 3.3 細胞 20 3.4 實驗方法 20 3.4.1 南嶺蕘花成份之分離及純化 20 3.4.2 細胞生長與分化之探討 24 3.4.3 細胞凋亡之探討 28 3.4.4 作用機制之探討 29 3.5 統計分析 30 第四章 結果 31 4.1 南嶺蕘花成份之分離純化 31 4.2 天然物活性成份AF與Daphnoretin誘導白血病細胞分化之細胞生物學研究 32 4.2.1 AF與Daphnoretin抑制人類白血病細胞株之生長 32 4.2.2 天然物AF對於U937細胞之細胞週期的影響 33 4.2.3 天然物AF誘導U937細胞之形態學變化 33 4.2.4 天然物AF誘導U937細胞分化後對NBT之還原能力 34 4.2.5 天然物AF誘導U937細胞分化後細胞吞噬能力之評估 34 4.2.6 天然物AF誘導U937細胞分化後表現單核球相關之表面抗原 34 4.2.7 天然物AF對於U937細胞之細胞週期的影響 35 4.2.8 天然物AF對於U937細胞產生Sub-G1期的評估 35 4.2.9 MAPK抑制劑對於天然物AF作用U937細胞生長抑制的影響 36 4.2.10 MAPK抑制劑對於天然物AF作用U937細胞之型態學變化 36 4.2.11 MAPK抑制劑對於天然物AF作用U937細胞NBT還原能力的影響 37 第五章 討論 38 5.1 在抑制生長(anti-proliferation)方面 39 5.2 在誘導分化(differentiation induction)方面 39 5.3 在細胞凋亡(Apoptosis)方面 40 5.4 在MAPK訊息傳遞方面 40 第六章 結論 44 6.1 總結 44 6.2 未來展望 45 參考文獻 47 圖一. 南嶺蕘花之有機溶劑分離流程示意圖 58 圖二. 純化南嶺蕘花中具有抗白血病活性成分之流程示意圖 59 圖三. HPLC分析Daphnoretin 60 圖四. LC-MS分析Daphnoretin 61 圖五. ¹H NMR分析圖譜 62 圖六. Daphnoretin化學結構圖 63 圖七. TLC分析AF與Daphnoretin 64 圖八. HPLC分析AF與Daphnoretin 65 圖九. 天然物AF與Daphnoretin抑制人類白血病U937細胞株之生長作圖 66 圖十. 流式細胞儀分析U937細胞之細胞週期 67 圖十一. 天然物AF對於人類白血病U937細胞株細胞週期之影響(G0/G1期) 68 圖十二. 天然物AF對於人類白血病U937細胞株細胞週期之影響(S期) 69 圖十三. 天然物AF對於人類白血病U937細胞株細胞週期之影響(G2/M期) 70 圖十四. U937細胞於光學顯微鏡(1000X)下細胞型態之變化 71 圖十五. 天然物AF誘導人類白血病U937細胞株分化之形態變化 72 圖十六. U937細胞於光學顯微鏡(1000X)下NBT反應之變化 73 圖十七. 天然物AF誘導人類白血病U937細胞株分化後NBT反應之能力 74 圖十八. U937細胞於光學顯微鏡(1000X)下吞噬能力之影響 75 圖十九. 天然物AF誘導人類白血病U937細胞株分化後吞噬能力之影響 76 圖二十. 流式細胞儀分析U937細胞之細胞表面抗原表現 77 圖二十一. 天然物AF誘導人類白血病U937細胞分化後表面抗原表現之影響 78 圖二十二. 凋亡小體於光學顯微鏡(1000X)下之型態 79 圖二十三. 流式細胞儀分析U937細胞之Sub-G1期分布 80 圖二十四. 天然物AF促進人類白血病U937細胞株Sub-G1期之產生 81 圖二十五. MAPK抑制劑對於天然物AF促進U937細胞株分化之細胞型態變化(400X) 82 圖二十六. MAPK抑制劑對於天然物AF抑制U937細胞株生長之影響 83 圖二十七. MAPK抑制劑對於天然物AF促進U937細胞株分化之型態學變化 84 圖二十八. MAPK抑制劑對於天然物AF促進U937

細胞株NBT 還原能力之影響 85 表一. 13C NMR分析Daphnoretin 86 表二. 1H NMR分析Daphnoretin 87 表三. 天然物AF抑制人類白血病U937細胞株之生長 88 表四. 天然物AF對於人類白血病U937細胞株細胞週期(G0/G1 期)之影響 89 表五. 天然物AF對於人類白血病U937細胞株細胞週期(S期)之影響 90 表六. 天然物AF對於人類白血病U937細胞株細胞週期(G2/M 期)之影響 91 表七. 天然物AF誘導人類白血病U937細胞株分化之形態變化 92 表八. 天然物AF誘導人類白血病U937細胞株分化後NBT反應 及吞噬能力之評估 93 表九. 天然物AF誘導人類白血病U937細胞分化後表面抗原之表現能力 94 表十. 天然物AF促進人類白血病U937細胞株Sub-G1期之產生 95 表十一. MAPK抑制劑對於天然物AF抑制U937細胞株生長之影響 96 表十二. MAPK抑制劑對於天然物AF誘導U937細胞分化之型態學變化 97 表十三. MAPK抑制劑對於天然物AF誘導U937細胞株NBT還 反應之影響 98 附錄一. 南嶺蕘花(*Wikstroemia indica* C.A. Mey.)之原植物形態 圖 99 附錄二. 南嶺蕘花 (*Wikstroemia indica* C.A. Mey.)中已發現之組 成分 100 附錄三. 南嶺蕘花 (*Wikstroemia indica* C.A. Mey.)已發現之成份 及其生物活性 101 附錄四. 急性白血病之分類 102 附錄五. 以型態學(FAB)分類之急性非淋巴球性白血病 103 附錄六. 細胞週期之示意圖 104 附錄七. MAPK signaling pathway 105 附錄八 MAPK signaling cascades . 106 附錄九. MAPK 抑制劑之結構 . 107 附錄十. MAPK抑制劑5-iodotubercidin及PD 98059於MAPK pathway中之抑制位置 . 108 附錄十一. MAPK抑制劑SB 203580 於MAPK pathway中之抑制位置 109

參考文獻

- 1.邱年永、張光雄(1983)原色臺灣藥用植物圖鑑,南天書局。
- 2.高木樹(1981)臺灣藥用植物手冊,南天書局。
- 3.歐潤芝(1998)臺灣中草藥圖鑑,三聯彩色印刷有限公司。
- 4.Ko FN, Chang YL, Ku YH, Lin YL and Teng CM (1993) Daphnoretin, a new protein kinase C activator isolated from *Wikstroemia indica* C. A. Mey. *Biochem. J.* 295:321-327.
- 5.Chen HC, Chou CK, Kuo YH and Yeh SF (1996) Identification of a protein kinase C (PKC) activator, daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells. *Biochem. Pharmacol.* 52:1025-1032.
- 6.Ke H, Hisayoshi K, Aijun D, Shigeo I and Xinsheng Y (2000) Antifungal, antimetabolic and anti-HIV-1 agents from the roots of *Wikstroemia indica*. *Planta Med.* 66:564-567.
- 7.Kato A, Hashimoto Y and Kidokoro M (1979) (+)-Nortrachelogenin, a new pharmacologically active lignan from *Wikstroemia indica*. *J. Nat. Prod.* 42:159-162.
- 8.Lee KH, Tagahara K, Suzuki H, Wu RY, Haruna M, Hall IH, Huang HC, Ito K, Iida T and Lai JS (1981) Antitumor agents. 49 tricin, kaempferol-3-O-beta-D-glucopyranoside and (+)- nortrachelogenin, antileukemic principles from *Wikstroemia indica*. *J. Nat. Prod.* 44:530-534.
- 9.Tseng KF and Chao TY (1963) Studies on the flavonoids present in chinese drugs. IX. A new flavone glycoside isolated from *Wikstroemia viridiflora*. *Yao Xue Xue Bao.* 10:286-292.
- 10.Chen CC, Lin YC, Chen YP and Hsu HY (1981) A study on the constituents of *Wikstroemia indica* C. A. Mey. *J. Taiwan Pharm. Assoc.* 33:28-29.
- 11.Harrison (1995) Harrison 's principles of internal medicine.
- 12.Maxwell MW (1982) *Clinical Hematology.*
- 13.Sundstrom C and Nilsson K (1976) Establishment and characterization of a human histiocytic lymphoma cell line U937. *Int. J. Cancer* 17:565-577.
- 14.Rabbins (1995) *Pathology.*
- 15.Olsson I and Breitman TR (1982) Induction of differentiation of the human histiocytic lymphoma cell line U937 by retinoic acid and cyclic adenosine 3',5'-monophosphate-inducing agents. *Cancer Res.* 42:3924-3927.
- 16.Hass R (1992) Retrodifferentiation- an alternative biological pathway in human leukemia cells. *Eur. J. cell Biol.* 58:1-11.
- 17.Yam LT, Li CY and Crosby WH (1971) Cytochemical identification of monocytes and granulocytes. *Am. J. Clin. Pathol.* 55:283-290.
- 18.Collins SJ, Ruscetti FW and Gallagher RE (1979) Normal functional characteristics of HL-60 after induction of differentiation by DMSO. *J. Exp. Med.* 149:969-974.
- 19.Baehner RL and Nathan DG (1968) Quantitative nitroblue tetrazolium test in chronic granulomatous disease. *New. Engl. J.* 278:971-976.
- 20.Janeway Jr. CA and Travers P (1994) *Immunobiology.*
- 21.Ault KA and Springer T (1981) Cross-reaction of rat-anti-mouse phagocyte-specific monoclonal activity (anti-mac-1) with human monocytes and NK cells. *J. Immunol.* 126:359-364.
- 22.Goyert SM, Ferrero EM, Semeritis SV, Winchester RJ, Silber J and Mattison AC (1986) Biochemistry and expression of myelomonocytic antigens. *J. Immunol.* 137:3909-3914.
- 23.Wang QH, Xie Y, Fan HH, Gao L and Liu Y (2003) Effects of hexamethylene bisacetamide on cell cycle and expression of its regulatory proteins in HL-60 cells. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 11:480-484.
- 24.Shih CR, Wu J, Liu Y, Liang YC, Lin SY, Sheu MT and Lee WS (2004) Anti-proliferation effect of 5,5-diphenyl-2-thiohydantoin (DPTH) in human vascular endothelial cells. *Biochem. Pharmacol.* 67:67-75.
- 25.Chiu LC, Ooi VE and Wan JM (2001) Eicosapentaenoic acid modulates cyclin expression and arrests cell cycle progression in human leukemic K-562 cells. *Int. J. Oncol* 19:845-849.
- 26.Shao ZM, Wu J, Shen ZZ and Barsky SH (1998) Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. *Anticancer Res.* 18:1435-1439.
- 27.Zeng XL and Tu ZG (2003) In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line. *Pharmacol. Toxicol.* 93:275-283.
- 28.Kerr JF, Wyllie AH and Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* 26:239-257.
- 29.Reed JC (1999) Mechanisms of apoptosis avoidance in cancer. *Curr. Opin. Oncol.* 11:68-74.
- 30.Fraser A and Evan G (1996) A license to kill. *Cell* 85: 781-784.
- 31.Andrew HW (1997) Apoptosis and carcinogenesis. *Eur. J. Cell Biol.* 73: 189-197.
- 32.Leaver HA, Whittle IR, Wharton SB and Ironside JW (1998) Apoptosis in human primary brain tumours. *Brit. J. Neurosurg.* 12: 539-546.
- 33.Dzau VJ, Gibbons GH, Mann M and Braun-Dullaeus R (1997) Future horizons in cardiovascular molecular therapeutics. *Am. J. Cardiol.* 80: 331-391.
- 34.Borisenko GG, Matura T, Liu SX, Tyurin VA, Jianfei J, Serinkan FB and Kagan VE (2003) Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells-existence of a threshold. *Arch. Biochem. Biophys.* 413:41-52.
- 35.Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M and Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from *Cannabis sativa*, on beta-amyloid-induced toxicity in PC12 cells. *J. Neurochem.* 89:134-141.
- 36.Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T and Altieri DC

(2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. *Clin. Cancer Res.* 9:2683-2692. 37. Gupta S (2002) Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). *Int. J. Oncol.* 22:15-20. 38. Reed JC (1995) Bcl-2 family protein: regulators of chemoresistance in cancer. *Toxicol Lett.* 82:155-158. 39. Han D, Chatterjee J, Early P, Pantazis EA and Wyche JH (1996) Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. *Cancer Res.* 56:1621-1628. 40. Reed JC (1997) Double identity for proteins of the Bcl-2 family. *Nature* 387:773-776. 41. Korsmeyer SJ (1999) Bcl-2 gene family and the regulation of programmed cell death. *Cancer Res.* 59: 1693-1700. 42. Herlaar E, Brawn Z (1999) p38 MAPK signaling cascades in inflammatory disease. *Mol. Med. Today* 5: 439-447. 43. Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. *Nat. Rev. Cancer* 3:55-56. 44. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathway mediated by ERK, JNK, and p38 protein kinase. *Science* 298: 1911-1912. 45. Teiji W, Josef M (2004) Mitogen-activated protein kinases in apoptosis regulation. *Oncogene* 23: 2838-2849. 46. Gallagher R, Collins S, Trujillo J, McCredie M, Ahearn M, Tsai S, Metzqar R, Aulakh G, Ting R, Ruscetti F and Gallo R (1979) Characterization of the continuous, differentiating cell line (HL-60) from a patient with acute promyelocytic leukemia. *Blood* 54:713-733. 47. Yen A, Brown D and Fishbaugh H (1987) Control of HL-60 monocytic differentiation. *Exp. Cell Res.* 168:247-254. 48. Denhardt DT (1996) Signal-transducing protein phosphorylation cascades mediated by Ras/Rho protein in the mammalian cell: the potential for multiplex signaling. *Biochem. J.* 318:729-747. 49. Takeda K, Iehiki T, Tokunou T, Lino N and Takeshita A (2001) 15-Deoxy-delta 12, 14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. *J. Biol. Chem.* 276: 48950-48955. 50. Kawakami S, Arai G, Hayashi T, Fujii Y, Xia G, Kageyama Y and Kihara K (2002) PPAR gamma ligands suppress proliferation of human urothelial basal cells in vitro. *J. Cell Physiol.* 191: 310-319. 51. Miwa Y, Sasaguri T, Lnoue H, Taba Y, Lshida A and Abumiya T (2000) 15-deoxy-Delta (12, 14)-prostaglandin J2 induces G1 arrest and differentiation marker expression in vascular smooth muscle cells. *Mol. Pharmacol.* 58: 837-844. 52. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K and Kiyosawa K (2002) Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. *Pancreas* 24: 1-7. 53. Wilmer WA, Dixon C, Lu L, Hilbelink T and Rovin BH (2001) A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARgamma. *Biochem. Biophys. Res. Commun.* 281: 57-62. 54. Kim MS, Lim WK, Cha JG, An NH, Yoo SJ, Park JH, Kim HM and Lee YM (2001) The activation of PI3-K and PKCzeta in PMA-induced differentiation of HL-60 cells. *Cancer Lett.* 171: 79-85. 55. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T and Kikkawa R (2000) Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. *Diabetes* 49: 1002-1032. 56. Huang WC, Chio CC, Chi KH, Wu HM and Lin WW (2002) Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferators activated receptor gamma agonists 15-deoxy-Delta (12, 14) prostaglandin J2, ciglitazone, and GW1929. *Exp. Cell Res.* 277: 192-200. 57. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J and Rapp UR (1994) The ins and outs of Raf kinases. *Trends. Biochem. Sci.* 19: 474-480. 58. Marais R, Light Y, Paterson HF and Marshall CJ (1995) Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. *EMBO. J.* 14: 3136-3145. 59. Hagemann C and Rapp UR (1999) Isotype-specific functions of Raf kinases. *Exp. Cell Res.* 253: 34-46. 60. Gold EJ, Mettelmann RH, Itri LM, Gee T, Arlin Z, Kempin S, Clarkson B and Moore Mas (1983) Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. *Cancer Treat. Rep.* 67:981-986. 61. Kieffler HP, Hirji K and Itri L (1985) In vivo and in vitro effects on human preleukemic and leukemic cells. *Cancer Treat. Rep.* 69:1399-1407. 62. Degos L, Castaigne S, Tilly H, Sigaux F and Daniel MT (1985) Treatment of leukemia with low-dose Ara-C: A study of 160 cases. *Sem. Oncol (Suppl 3)* 12:196-199. 63. <http://www.nobel.se/medicine/laureates/2001/press.html> 64. http://www.cellsignal.com/reference/pathway/MAPK_Cascade.asp 65. <http://www.cellsignal.com/reference/pathway/MAPKERK.asp> 66. <http://www.cellsignal.com/reference/pathway/p38MAPK.asp>